Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne

An Open Label Pilot Clinical Trial on the Efficacy and Safety of ProOxy Facial Spray (Topical 15% Oxygen Solution) in the Treatment of Moderate Facial Acne Vulgaris Among Filipino Patients

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01682200

Enrollment

Registered

2012-09-10

Start date

2009-10-31

Completion date

2011-09-30

Last updated

2012-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

moderate, facial acne, acne vulgaris

Brief summary

This study was conducted to determine the effects and side effects of ProOxy facial spray in the treatment of acne.

Detailed description

A study on the effects and side effects of ProOxy facial spray was done. Sixty people were selected and approved to participate in this study. Pictures of the face (frontal,left side and right side) were taken upon acceptance, during and after treatment at 4,8 and 12 weeks intervals.

Interventions

DRUGProOxy

Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with acne on their faces only * patients who are at least 18 years of age * patients who have normal and disease free skin at the dorsal surface of the upper arm. * patients who are willing to follow instructions on both the Patch Test Part one and Part Two procedures and to follow scheduled visits.

Exclusion criteria

* patients with systemic illnesses(such as but not limited to heart disease, hypertension, diabetes, cancer, liver disease, kidney disease) * patients with very dark skin color, Fitzpatrick skin type V-VI, who are prone to post=inflammatory hyperpigmentation. * patients with intake of oral medications including glucocorticoids or any immuno-suppressants or who have undergone ultraviolet phototherapy for the past 2 weeks prior to the patch test. * patients with history of contact dermatitis, dermatographism or anaphylaxis. * patients with history of eczematous and inflammatory dermatitis, seborrheic dermatitis and psoriasis.

Design outcomes

Primary

Measure	Time frame	Description
Changes in the appearances,sizes of the acne lesions as well as the disappearance of acne on the face.	4,8,12 weeks post application of the spray	Upon acceptance,pictures are taken and acne lesions are identified and counted and after 4,8, and 12 weeks during and after application of ProOxy.

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026